Results 51 to 60 of about 58,029 (309)

IVIg treatment reduces catalytic antibody titers of renal transplanted patients. [PDF]

PLoS ONE, 2013
Catalytic antibodies are immunoglobulins endowed with enzymatic activity. Catalytic IgG has been reported in several human autoimmune and inflammatory diseases.
Ankit Mahendra, Ivan Peyron, Cécile Dollinger, Laurent Gilardin, Meenu Sharma, Bharath Wootla, Séverine Padiolleau-Lefevre, Alain Friboulet, Didier Boquet, Christophe Legendre, Srinivas V Kaveri, Olivier Thaunat, Sébastien Lacroix-Desmazes   +12 more
doaj   +1 more source

Controversies in the Use of Passive Immunotherapy for Bacterial Infections in the Critically Ill Patient [PDF]

, 2017
Several preparations of standard immunoglobulins for intravenous use have been tested as adjunctive therapy for bacterial infections in premature neonates and in critically ill adults after major surgery, trauma, and burn.
Baumgartner, J. D., Glauser, M. P.
core  

Detection of antibodies to Sendai virus by enzyme-linked immunosorbent assay (ELISA) [PDF]

, 1979
An enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to Sendai virus, a paramyxovirus, is described. The assay was found to be about 20-fold more sensitive than the hemagglutination inhibition assay.
Avrameas, Bennink, Doherty, Doherty, Ertl, Gerhard, Hunter, Koszinowski, Koszinowski, Koszinowski, Leinikki, Lowry, Nakane, Ornstein, Roberts, Salk, Svenag, White   +17 more
core   +1 more source

Insights Into the Antigenic Repertoire of Unclassified Synaptic Antibodies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We sought to characterize the sixth most common finding in our neuroimmunological laboratory practice (tissue assay‐observed unclassified neural antibodies [UNAs]), combining protein microarray and phage immunoprecipitation sequencing (PhIP‐Seq). Methods Patient specimens (258; 133 serums; 125 CSF) meeting UNA criteria were profiled;
Michael Gilligan, John R. Mills, Paulina Vargas, Naveen K. Paramasivan, Connie E. Lesnick, Eati Basal, Surendra Dasari, James P. Fryer, Shannon R. Hinson, Joseph Laporta, Amy Espinal, Dennis Fitzgerald, Carolina Garcia, Anna E. Morenkova, Paola Pergami, Anna Shah, Andrew Knight, Reghann LaFrance Corey, Vanda A. Lennon, Anastasia Zekeridou, Sean J. Pittock, Divyanshu Dubey, Andrew McKeon   +22 more
wiley   +1 more source

Eosinophilic meningoencephalitis successfully treated with glucocorticoids and intravenous immunoglobulin: a case report [PDF]

Encephalitis
Eosinophilic meningoencephalitis is a rare inflammatory condition of the central nervous system. As a limited number of cases has been reported, debate remains on the optimal treatment.
Soo Hyun Ahn, Seon-Jae Ahn, Seung Ae Kim, Han Sang Lee, Kon Chu   +4 more
doaj   +1 more source

Intravenous immunoglobulins for epilepsy [PDF]

Cochrane Database of Systematic Reviews, 2010
Epilepsy is a common neurological condition, with an estimated incidence of 50 per 100,000 persons. People with epilepsy may present with various types of immunological abnormalities, such as low serum immunoglobulin A (IgA) levels, lack of the immunoglobulin G (IgG) subclass and identification of certain types of antibodies. Intravenous immunoglobulin
Jinsong, Geng, Jiancheng, Dong, Youping, Li, Hengjian, Ni, Kui, Jiang, Li Li, Shi, Guohua, Wang   +6 more
openaire   +5 more sources

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis

Scientific Reports, 2020
Corticosteroids may produce a paradoxical worsening of myasthenia gravis (MG) symptoms within the first weeks of treatment. We therefore wanted to assess the hypothesis that a prior infusion of intravenous immunoglobulin (IVIG) may have a protective ...
Laura Díez-Porras, Christian Homedes, Maria Antonia Alberti, Valentina Vélez-Santamaría, Carlos Casasnovas   +4 more
doaj   +1 more source

Human parvovirus B19 and blood product safety. A tale of twenty years of improvements [PDF]

, 2015
Parvovirus B19 (B19V), long known to be the causative agent of erythema infectiosum (fifth disease), is not a newly emerging agent. The aim of this review is to analyse the role played by this virus in compromising safety in transfusion medicine and the ...
Calizzani, Gabriele, Candura, Fabio, Facco, Giuseppina, Grazzini, Giuliano, Liumbruno, Giancarlo M., Marano, Giuseppe, Pupella, Simonetta, VAGLIO, Stefania   +7 more
core   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source